Ralf Pasternack

Darmstadt, HE, Germany

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 17 publications

Transcriptomic analysis of intestine following administration of a transglutaminase 2 inhibitor to prevent gluten-induced intestinal damage in celiac disease.

Transcriptomic analysis of intestine following administration of a transglutaminase 2 inhibitor to prevent gluten-induced intestinal damage in celiac disease.

Journal: Nature immunology

Published: June 22, 2023

The Oral Transglutaminase 2 Inhibitor ZED1227 Accumulates in the Villous Enterocytes in Celiac Disease Patients during Gluten Challenge and Drug Treatment.

The Oral Transglutaminase 2 Inhibitor ZED1227 Accumulates in the Villous Enterocytes in Celiac Disease Patients during Gluten Challenge and Drug Treatment.

Journal: International journal of molecular sciences

Published: May 16, 2023

Features of ZED1227: The First-In-Class Tissue Transglutaminase Inhibitor Undergoing Clinical Evaluation for the Treatment of Celiac Disease.

Features of ZED1227: The First-In-Class Tissue Transglutaminase Inhibitor Undergoing Clinical Evaluation for the Treatment of Celiac Disease.

Journal: Cells

Published: March 31, 2022

Clinical Validation of an Automated Fluorogenic Factor XIII Activity Assay Based on Isopeptidase Activity.

Clinical Validation of an Automated Fluorogenic Factor XIII Activity Assay Based on Isopeptidase Activity.

Journal: International journal of molecular sciences

Published: December 22, 2020

Editorial for the special issue on transglutaminases in translation - Novel tools and methods impacting on diagnostics and therapeutics.

Editorial for the special issue on transglutaminases in translation - Novel tools and methods impacting on diagnostics and therapeutics.

Journal: Analytical biochemistry

Published: August 04, 2020

Structure-Based Design of FXIIIa-Blockers: Addressing a Transient Hydrophobic Pocket in the Active Site of FXIIIa.

Structure-Based Design of FXIIIa-Blockers: Addressing a Transient Hydrophobic Pocket in the Active Site of FXIIIa.

Journal: ChemMedChem

Published: January 30, 2020

Feasibility of an automated coagulation factor XIIIa test using its isopeptidase activity.

Feasibility of an automated coagulation factor XIIIa test using its isopeptidase activity.

Journal: Analytical biochemistry

Published: January 20, 2020

Nucleotide binding kinetics and conformational change analysis of tissue transglutaminase with switchSENSE.

Nucleotide binding kinetics and conformational change analysis of tissue transglutaminase with switchSENSE.

Journal: Analytical biochemistry

Published: December 20, 2019

Novel inhibitor ZED3197 as potential drug candidate in anticoagulation targeting coagulation FXIIIa (F13a).

Novel inhibitor ZED3197 as potential drug candidate in anticoagulation targeting coagulation FXIIIa (F13a).

Journal: Journal of thrombosis and haemostasis : JTH

Published: June 19, 2019

In vivo evaluation of two tissue transglutaminase PET tracers in an orthotopic tumour xenograft model.

In vivo evaluation of two tissue transglutaminase PET tracers in an orthotopic tumour xenograft model.

Journal: EJNMMI research

Published: February 28, 2018

Microbial Transglutaminase Used in Bread Preparation at Standard Bakery Concentrations Does Not Increase Immunodetectable Amounts of Deamidated Gliadin.

Microbial Transglutaminase Used in Bread Preparation at Standard Bakery Concentrations Does Not Increase Immunodetectable Amounts of Deamidated Gliadin.

Journal: Journal of agricultural and food chemistry

Published: July 20, 2017

Development of fluorine-18 labeled peptidic PET tracers for imaging active tissue transglutaminase.

Development of fluorine-18 labeled peptidic PET tracers for imaging active tissue transglutaminase.

Journal: Nuclear medicine and biology

Published: August 05, 2016

Showing 1-12 of 17

Last Updated: 09/26/2026